RCRoque Cardona-Hernandez

Roque Cardona-Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roque Cardona-Hernandez has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monitorización continua de cuerpos cetónicos en personas con diabetes como tecnología emergente: consideraciones prácticas adaptadas al contexto asistencial español

    by Rosa Corcoy, Pilar Isabel Beato-Víbora, Margarita Giménez, Martín Cuesta, Roque Cardona-Hernandez, Diego Fernández-García, Alberto de la Cuadra-Grande

  • Open Access

    Insulin pens and the digital ecosystem

    by Johan Jendle, Peter Adolfsson, Roque Cardona-Hernandez, Laurent Crenier, Sergio Di Molfetta, Dominic Ehrmann, Francesco Giorgino, Martin Haluzik, Irl B. Hirsch, Concetta Irace, et al.

    Insulin has been used for over a century for the treatment of diabetes and, since the mid-1980s, there has been a rapid development of insulin administration tools. Over the last decade, several medical products used for diabetes management have been connected to a digital ecosystem. This connectivity includes sophisticated monitoring of not only glucose levels but also of insulin delivery (type, dose, time of dosing). It facilitates interactions between people with diabetes, various diabetes technology devices and healthcare professionals. This white paper aims to discuss and categorise different types of insulin pens, connected insulin pens and caps, as well as smart insulin pen systems (SPSs) that are available on the market. Connected pens capture data to provide information about the details of the insulin applied. SPSs are paired with a continuous glucose monitoring (CGM) system and, by means of integrated algorithms, can provide individualised dose calculation based on a variety of factors. These SPSs can also recommend insulin doses based on current and projected glucose and insulin data; this feature requires a connection to a CGM system. Yet what are the clinical advantages of SPSs? What added value does this system bring to individuals living with diabetes and their healthcare providers? In a narrative review, we discuss the current regulatory pathways and market environment as well as the influencing factors of connected insulin pens vs SPSs. We aim to provide a rationale and justification for this categorisation based on (smart) design aspects, regulatory considerations and clinical outcomes. This review concludes that while standard insulin pens remain a safe and commonly offered option, connected insulin pens and SPSs are likely to show improvement in glycaemic management, treatment adherence and patient satisfaction, and represent a significant advancement in diabetes care. However, further research including high-quality clinical and health economic studies will be vital in substantiating the value of both connected insulin pens and SPSs and driving broader acceptance among payers and healthcare systems. Graphical Abstract

  • Open Access

    Recomendaciones clínicas para el manejo de pacientes con diabetes tipo 1 en situaciones especiales

    by Estela Gil Poch, Marta Ferrer Lozano, Marta Murillo Vallés, Roque Cardona-Hernandez, María Clemente León, Nerea Itza Martín, Isabel Leiva-Gea, Jacobo Pérez Sánchez, Purificación Ros Pérez, M. Pilar Bahillo Curieses

  • Open Access

    ISPAD Position Statement on Type 1 Diabetes in Schools

    by P.W. Goss, N. Bratina, L.E. Calliari, R. Cardona-Hernandez, K. Lange, S.E. Lawrence, C.A. March, G. Forsander


  • Open Access

    Basal and Bolus Insulin Distribution According to Treatment Modality: Data from SWEET Diabetes Registry

    by Ferda Evin, Sascha R. Tittel, Barbara Piccini, Roque Cardona-Hernandez, Dick Mul, Nicole Sheanon, Thekla von Dem Berge, Vit Neuman, Martin Tauschmann, Damla Gökşen

    Background and Aims. The optimal basal and bolus insulin distribution in type 1 diabetes (T1D) is still controversial. Herein, we aimed to determine the variability of basal to total daily insulin dose according to treatment modality and diabetes technologies from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) registry. Methods. The study cohort was generated by using the SWEET database. Patients with T1D for at least 2 years, aged between 2.5 and 18 years, with at least one clinic visit between June 2010 and June 2021, were included in the study. Four groups were composed according to treatment modality as follows: multiple daily injections (MDI) without continuous glucose monitoring (CGM); MDI with CGM; subcutaneous insulin infusion (CSII) without CGM; and CSII with CGM. Data of the participants were analyzed and compared for each treatment modality separately. Results. A total of 38,956 children and adolescents were included in the study. Of the study sample, 48.6% were female, the median (range) age was 15.2 (11.9–17.2) years, and the median diabetes duration was 6.0 (3.8–9.0) years. The distribution of treatment modality was as follows: MDI without CGM, 32.9%; MDI with CGM, 18.0%; CSII without CGM, 11.7%; and CSII with CGM, 37.3%. In unadjusted data, regardless of treatment modality, all the analyses revealed a significant association between basal dose to total daily insulin dose (BD/TDD) with male gender, younger age group, and lower HbA1c, which were all related to a decreased ratio of BD/TDD (all ). There was no association between BD/TDD and different diabetes technologies after the age, gender, and diabetes duration were adjusted. Conclusions. Herein, we showed that there was an association between lower proportions of basal to total insulin and lower hemoglobin A1c in a large cross-sectional cohort of children who had T1D. There was also an association between lower BD/TDD and younger age. There was no significant difference between BD/TDD ratios under different diabetes technologies (CGM and/or CSII).


  • Open Access

    New therapies towards a better glycemic control in youths with type 1 diabetes

    by Roque Cardona-Hernandez, Klemen Dôvc, Torben Biester, Laya Ekhlaspour, Maddalena Macedoni, Martin Tauschmann, Chiara Mameli


  • Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review

    by Chiara Mameli, Giulia Marie Smylie, Alessio Galati, Biagio Rapone, Roque Cardona-Hernandez, Gianvincenzo Zuccotti, Maurizio Delvecchio

    Hybrid closed loop (HCL) systems are the combination of a pump for insulin delivery and a glucose sensor for continuous glucose monitoring. These systems are managed by an algorithm, which delivers insulin on the basis of the interstitial glucose levels. The MiniMed™ 670G system was the first HCL system available for clinical purpose. In this paper, we reviewed the literature about metabolic and psychological outcomes in children, adolescents and young adults with type 1 diabetes treated with MiniMed™ 670G. Only 30 papers responded to the inclusion criteria and thus were considered. All the papers show that the system is safe and effective in managing glucose control. Metabolic outcomes are available up to 12 months of follow-up; longer study period are lacking. This HCL system may improve HbA1c up to 7.1% and time in range up to 73%. The time spent in hypoglycaemia is almost neglectable. Better improvement in blood glucose control is observed in patients with higher HbA1c at HCL system start and larger daily use of auto-mode functionality. Conclusion: The Medtronic MiniMed™ 670G is safe and well accepted, without any increase in the burden for patients. Some papers report an improvement in the psychological outcomes, but other papers do not confirm this finding. So far, it significantly improves the management of diabetes mellitus in children, adolescents and young adults. Proper training and support by the diabetes team are mandatory. Studies for a period longer than 1 year would be appreciated to better understand the potentiality of this system. What is Known: • The Medtronic MiniMedTM 670G is a hybrid closed loop system which combines a continuous glucose monitoring sensor with an insulin pump. • It has been the first hybrid closed loop system available for clinical purpose. Adequate training and patients support play a key role in diabetes management. What is New: • The Medtronic MiniMedTM 670G may improve HbA1c and CGM metrics up to 1-year of follow-up, but the improvement appears lower than advanced hybrid closed loop systems. This system is effective to prevent hypoglycaemia. • The psychosocial effects remain less understood in terms of improvement of psychosocial outcomes. The system has been considered to provide flexibility and independence by the patients and their caregivers. The workload required to use this system is perceived as a burden by the patients who decrease the use of auto-mode functionality over time.


  • Open Access

    Type 1 Diabetes Patient Experiences Before and After Transfer from a Paediatric to an Adult Hospital

    by Mercè Vidal Flor, Margarida Jansà i Morató, Carmen Yoldi Vergara, Roque Cardona-Hernández, Marga Giménez Alvárez, Ignacio Conget Donlo, Pilar Isla Pera

    Introduction: The management of type 1 diabetes (T1D) is especially complex during adolescence when youths are transferred to adult care centres. The objectives of this qualitative study were to: a) determine the expectations of young T1D patients prior to transfer, b) evaluate the transfer process between the 2 centres, and c) evaluate the therapeutic education and care programme (TECP) in the adult centre from their point of view. Material and Methods: Opinion sampling of adolescents from 2018– 2019 was performed: Phase 1: adolescents with T1D prior to transfer to the adult hospital; Phase 2: adolescents with T1D one or two years after transfer and having undergone TECP. A focus group (1.5h) and semi-structured interviews (45 min) were performed and taped, transcribed, and sent to the participants for confirmation. Date analysis was performed of the transcriptions of the focus group and interviews. Fragments were selected and meta-categories created. Results: Eleven youths accepted to participate: 7 in Phase 1, 4 repeated in Phase 2 and 4 more transferred 2 years previously were added. The meta-categories obtained were: 1) perception of the quality of care and therapeutic education in the paediatric hospital. 2) transfer to the adult hospital. 3) experience of the youths 1– 2 years after transfer and having undergone TECP. The data are presented in narrative form and are supported with text fragments of the participants’ discussions. Discussion and conclusions: Analysis of patients’ experience complemented by clinical-educational evaluation of TECP provides understanding of the perspectives of youths on the complexity of living with a chronic disease since childhood. It also provides information regarding the factors favouring quality care and therapeutic education, the complexity of transfer from paediatric to adult care, determination of the strong and weak points and the establishment of strategies to improve the programme.


  • Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET

    by Roque Cardona-Hernandez, Anke Schwandt, Hessa Alkandari, Heiko Bratke, Agata Chobot, Nicole Coles, Sarah Corathers, Damla Goksen, Peter Goss, Zineb Imane, et al.

    OBJECTIVE Insulin delivery methods, glucose-monitoring modalities, and related outcomes were examined in a large, international, diverse cohort of children and adolescents with type 1 diabetes from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) -Registry. RESEARCH DESIGN AND METHODS Participants with type 1 diabetes of ≥1 year, aged ≤18 years, and who had documented pump or sensor usage during the period August 2017–July 2019 were stratified into four categories: injections–no sensor (referent); injections + sensor; pump–no sensor; and pump + sensor. HbA1c and proportion of patients with diabetic ketoacidosis (DKA) or severe hypoglycemia (SH) were analyzed; linear and logistic regression models adjusted for demographics, region, and gross domestic product per capita were applied. RESULTS Data of 25,654 participants were analyzed. The proportions of participants (adjusted HbA1c data) by study group were as follows: injections–no sensor group, 37.44% (8.72; 95% CI 8.68–8.75); injections + sensor group, 14.98% (8.30; 95% CI 8.25–8.35); pump–no sensor group, 17.22% (8.07; 95% CI 8.03–8.12); and pump + sensor group, 30.35% (7.81; 95% CI 7.77–7.84). HbA1c was lower in all categories of participants who used a pump and/or sensor compared with the injections–no sensor treatment method (P < 0.001). The proportion of DKA episodes was lower in participants in the pump + sensor (1.98%; 95% CI 1.64–2.48; P < 0.001) and the pump–no sensor (2.02%; 95% CI 1.64–2.48; P < 0.05) groups when compared with those in the injections–no sensor group (2.91%; 95% CI 2.59–3.31). The proportion of participants experiencing SH was lower in pump–no sensor group (1.10%; 95% CI 0.85–1.43; P < 0.001) but higher in the injections + sensor group (4.25%; 95% CI 3.65–4.95; P < 0.001) compared with the injections–no sensor group (2.35%; 95% CI 2.04–2.71). CONCLUSIONS Lower HbA1c and fewer DKA episodes were observed in participants using either a pump or continuous glucose monitoring (CGM) or both. Pump use was associated with a lower rate of SH. Across SWEET centers, use of pumps and CGM is increasing. The concomitant use of pump and CGM was associated with an additive benefit.


  • Open Access

    Children and youth with diabetes are not at increased risk for hospitalization due to COVID ‐19

    by Roque Cardona‐Hernandez, Valentino Cherubini, Dario Iafusco, Riccardo Schiaffini, Xiaoping Luo, David M. Maahs

    The severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2), responsible for the coronavirus disease COVID‐19, was first identified in Wuhan, China in December 2019. Diabetes, as well as other cardiovascular comorbidities, has been recognized as a major risk factor for outcomes and mortality in adults with COVID19, particularly in the elderly with type 2 diabetes. Based on these conclusions, COVID‐19 data on adults have been generalizedto youth with diabetes. Nevertheless, experience from Pediatric Diabetes practices in China (Wuhan), Italy, Spain (Catalonia) and the US (San Francisco Bay Area) consistently report only a single severe case of COVID‐19 in a 20‐year‐old female youth with type 1 diabetes (T1D) that was hospitalized for bilateral pneumonia and was subsequently discharged without complications. In Italy, information on COVID‐19 in all children with diabetes is collected on a weekly basis andthose with positive swab test or infection‐related symptoms reported to a dedicated national registry. Of a total of 15,500 children tested,11subjects with T1D (age 8‐17y) tested positive for COVID‐19; 6/11 were asymptomatic and the rest presented with mild symptoms. In the rest of locations, youth with T1D diagnosed with COVID‐19 were based on clinical suspicion and a confirmatory PCR test(Wuhan:0; Catalonia‐HSJD:3; California‐Stanford:2) and all of them were asymptomatic or had a mild course.We suggest that COVID‐19 data from adults should not be generalizedto children, adolescents and youth with diabetes as their outcomes and prognosis seem to be similar to their non‐diabetic‐peers and consistently milder than adults with diabetes.